1. |
DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin, 2014, 64(1):52-62.
|
2. |
Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst, 1998, 90(11):814-823.
|
3. |
Zhao M, Ramaswamy B. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World J Clin Oncol, 2014, 5(3):248-262.
|
4. |
Nilsson S, Gustafsson JA. Estrogen receptors:therapies targeted to receptor subtypes. Clin Pharmacol Ther, 2011, 89(1):44-55.
|
5. |
Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer, 2011, 11(8):597-608.
|
6. |
Frasor J, Danes JM, Komm B, et al. Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells:insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology, 2003, 144(10):4562-4574.
|
7. |
Klinge CM. Estrogen receptor interaction with co-activators and co-repressors. Steroids, 2000, 65(5):227-251.
|
8. |
Levin ER, Pietras RJ. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat, 2008, 108(3):351-361.
|
9. |
Revankar CM, Cimino DF, Sklar LA, et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science, 2005, 307(5715):1625-1630.
|
10. |
Sachdev JC, Jahanzeb M. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer. Clin Breast Cancer, 2012, 12(1):19-29.
|
11. |
Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifenresistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat, 1992, 24(2):85-95.
|
12. |
Giordano C, Catalano S, Panza S, et al. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene, 2011, 30(39):4129-4140.
|
13. |
Knowlden JM, Hutcheson IR, Jones HE, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology, 2003, 144(3):1032-1044.
|
14. |
Hurtado A, Holmes KA, Geistlinger TR, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature, 2008, 456(7222):663-666.
|
15. |
Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol, 2011, 29(33):4452-4461.
|
16. |
Morelli C, Garofalo C, Bartucci M, et al. Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells. Oncogene, 2003, 22(26):4007-4016.
|
17. |
Parisot JP, Leeding KS, Hu XF, et al. Induction of insulin-like growth factor binding protein expression by ICI 182780 in a tamoxifen-resistant human breast cancer cell line. Breast Cancer Res Treat, 1999, 55(3):231-242.
|
18. |
Lisztwan J, Pornon A, Chen B, et al. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factorⅠreceptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res, 2008, 10(4):R56.
|
19. |
Milano A, Dal Lago L, Sotiriou C, et al. What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer, 2006, 42(16):2692-2705.
|
20. |
Ciruelos Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev, 2014, 40(7):862-871.
|
21. |
Provenzano A, Kurian S, Abraham J. Overcoming endocrine resistance in breast cancer:role of the PI3K and the mTOR pathways. Expert Rev Anticancer Ther, 2013, 13(2):143-147.
|
22. |
Creighton CJ, Fu X, Hennessy BT, et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+breast cancer. Breast Cancer Res, 2010, 12(3):R40.
|
23. |
Chen X, Zhao M, Hao M, et al. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer. Mol Cancer Res, 2013, 11(10):1269-1278.
|
24. |
Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 2014, 507(7492):315-322.
|
25. |
Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med, 2011, 62:233-247.
|
26. |
Brodie A, Jelovac D, Sabnis G, et al. Model systems:mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol, 2005, 95(5):41-48.
|
27. |
Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer:results from the randomized phaseⅢTAnDEM study. J Clin Oncol, 2009, 27(33):5529-5537.
|
28. |
Huober J, Fasching PA, Barsoum M, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer-results of the eLEcTRA trial. Breast, 2012, 21(1):27-33.
|
29. |
Cristofanilli M, Valero V, Mangalik A, et al. PhaseⅡ, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res, 2010, 16(6):1904-1914.
|
30. |
Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol, 2009, 27(33):5538-5546.
|
31. |
Mayer IA, Abramson VG, Isakoff SJ, et al. Stand up to cancer phaseⅠb study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol, 2014, 32(12):1202-1209.
|
32. |
Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-classⅠPI3-kinase inhibitor. Mol Cancer Ther, 2012, 11(2):317-328.
|
33. |
Bachelot T, Bourgier C, Cropet C, et al. Randomized phaseⅡtrial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors:a GINECO study. J Clin Oncol, 2012, 30(22):2718-2724.
|
34. |
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med, 2012, 366(6):520-529.
|
35. |
Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phaseⅢplacebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol, 2013, 31(2):195-202.
|
36. |
Robertson JF, Ferrero JM, Bourgeois H, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer:a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol, 2013, 14(3):228-235.
|